Hyperuricemia - risk marker of endothelial dysfunction in the development of erectile dysfunction


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents the modern literature data indicating the importance of evaluation of the role of hyperuricemia as a cause of endothelial dysfunction and oxidative stress in the pathogenesis of cardiovascular diseases (CVD) and erectile dysfunction (ED). It is hypothesized that hyperuricemia can really affect the outcomes of vascular lesions, and the use of diets and medicines aimed at reducing the uric acid levels, therefore, may be a new method of prevention of cardiovascular diseases, erectile dysfunction, and renal glomerular lesions. Further research in this area will soon have to give answers to these questions.

Full Text

Restricted Access

About the authors

V. S Saenko

SBEI HPE First MSMU n.a. I.M. Sechenov of RMPH

Email: saenko_vs@mail.ru
MD, Assistant Professor at the Department of Urology

A. Z Vinarov

SBEI HPE First MSMU n.a. I.M. Sechenov of RMPH

SRI of Uronephrology and Reproductive Human Health

S. V Pesegov

SBEI HPE First MSMU n.a. I.M. Sechenov of RMPH

Clinic of Urology ECH № 2 of the Clinical Center

References

  1. Бритов А.Н. Вопросы профилактики и лечения гипертонии на популяционном уровне. Клин. Мед. 1984; 9: 43-49.
  2. Ruilope L.M., Garcia-Puig J. Hyperuricemia and Renal Function. Curr. Hypertens. Rep. 2001; 3: 197-202.
  3. Shiri R., Koskimaki J., Hakkinen J. et al. Tampere Ageing Male Urological Study. Effects of age, comorbidity and lifestyle factors on erectile function: Tampere Ageing Male Urological Study (TAMUS). Eur. Urol. 2004; 45: 628-633.
  4. Choi H.K., Atkinson K., Karlson E.W. et al. Obesity, weight change, hypertension, diuretic use, and risk of gout in men the Health Professionals Follow-up Study. Arch. Intern. Med. 2005; 165: 742-748.
  5. Dessein P.H., Shipton E.A., Stanwix A.E. et al. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann. Rheum. Dis. 2000; 59: 539-543.
  6. Fam A.G. Gout, diet, and the insulin resistance syndrome. J. Rheumatol. 2002; 29(7): 1350-1355.
  7. Lin K.C., Lin H.Y., Chou P. Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen. J. Rheum. 2000; 27: 1045-1050.
  8. Alper A.B. Jr., Chen W., Yau L. et al. Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study. Hypertension. 2005; 45: 34-38.
  9. Grodzicki T., Palmer A., Bulpitt C.J. Incidence of diabetes and gout in hypertensive patients during 8 year of follow-up. J. Hum Hypertens. 1997; 11: 583-585.
  10. Fang J., Alderman M. Serum uric acid and cardiovascular mortality: The NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA. 2000; 238: 2404-2410.
  11. Johnson R.J., Kang D.H., Feig D. et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003; 41(6): 1183-1190.
  12. Mazzali M., Hughes J., Kim Y.G. et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001; 38(5): 1101-1106.
  13. Tykarski A. Evaluation of renal handling of uric acid in essential hypertension: hyperuricemia related to decreased urate secretion. Nephron. 1991; 59: 364-368.
  14. Breckenridge A. Hypertension and hyperuricaemia. Lancet. 1966; 1: 15-18.
  15. US Renal Data System. USRDS 1999 annual data report. Bethesda (MD): National Institute of Health (US), National Institute of diabetes and Digestive and Kidney Diseases. 1999.
  16. Ahn K.J., Kim Y.S., Lee H.C. et al. Cyclosporine-induced hyperuricemia after renal transplant: clinical characteristics and mechanisms. Transplant. Proc. 1992; 24: 1391-1392.
  17. Saag K.G., Choi H. Epidemiology, risk factors, and life style modifications forgout. Arthritis Res. Ther. 2006; 8(Suppl. 1): S2.
  18. Ревматология: национальное руководство, 2008.
  19. Zhang W., Doherty M., Pascual E. et al. EULA Revidence based recommendation sforgout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1301-1311.
  20. Orowan E. The origin of man. Nature 1955; 175: 683-684.
  21. Bloch S., Brackenridge C.J. Psychological, performance and biochemical factors in medical students under examination stress. J Psychosom. Res. 1972; 16: 25-33.
  22. Brooks G.W., Mueller E. Serum urate concentrations among university professors; relation to drive, achievement, and leadership. JAMA. 1966; 195: 415-418.
  23. Stetten D. Jr., Hearon J.Z. Intellectual level measured by army classification battery and serum uric acid concentration. Science 1959; 129: 1737.
  24. Ames B.N., Cathcart R., Schwiers E. et al. Uric acid provides an antioxidant defense in humans against oxidant - and radical-caused aging and cancer: a hypothesis. Proc. Natl. Acad. Sci. USA. 1981; 78: 6858-62.
  25. Waring W.S., McKnight J.A., Webb D.J. et al. Uric acid restores endothelial function in patients with type 1 diabetes and regular smokers. Diabetes. 2006; 55: 3127-132.
  26. Krishnan E., Chen L., Schumacher H.R. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med. 2005; 118: 816-826.
  27. Johnson R.J., Titte S., Cade J.R. et al. Uric acid, evolution and primitive cultures. Semin. Nephrol. 2005; 25: 3-8.
  28. Johnson R.J., Kang D.H., Feig D. et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003; 41: 1183-1190.
  29. Nakanishi N., Okamoto M., Yoshida H. et al. Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur. J. Epidemiol. 2003; 18: 523-530.
  30. Kang D.H., Park S.K., Jonson R.J. Uric-acid C-reactiv protein expression: implication on cell proliferation and nitricoxide production of human vascular cells. J. Am. Soc. Nephrol. 2005; 16: 3553-3562.
  31. Jonson R.J., Rodriguez-Iturbe B. Etal. A uniflying path way for essential hypertension. Am. J. Hypertens. 2005; 18: 431-440.
  32. Kanellis J., Kang D.H. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin. Nephrol 2005; 25: 39-42.
  33. Leyva F., Anker S., Swan J.W. et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur. Heart J. 1997; 18: 858-865.
  34. Coutinho T. de A., Turner S.T. Peyser P.A. et al. Associations of serum uric asid with markers of inflammation, metabolic syndrome, and subclinical coronary atherosclerosis. Am. J. Hepertens. 2007; 20: 83-89.
  35. Verdecchia P., Schillaci G., Reboldi G. et al. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PUIMA study. Hypertension. 2000. 36: 1072.
  36. Anker S.D., Doehner W., Rauchhaus M. et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation. 2003. 107: 1991-1997.
  37. Culleton B.F., Larson M.G., Kannel W.B. et al. Serum Uric Acid and Risk for Cardiovascular Disease and Death: The Framingham Heart Study. Ann. Intern. Med. 1999; 131: 7-13.
  38. Leyva F., Anker S., Godsland I.F. et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur. Heart. J. 1998; 19(12): 1814-1822.
  39. Rao G.N., Corson M.A., Berk B.C. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A- chain expression. J. Biol. Chem. 1991; 266: 8604-8608.
  40. Schumacher H.R. Jr. Crystal-induced arthritis: an overview. Am. J. Med. 1996; 100: 46S-52S.
  41. Насонов Е.Л. Проблема атеротромбоза в ревматологии. Вестник РАМН. 2003; 7: 6-10.
  42. Насонов Е.Л., Насонова В.А., Барскова В.Г. Механизмы развития подагрического воспаления. Терапевтический архив. 2006; 6: 77-84.
  43. Johnson R.J., Rodriguez-Iturbe B., Kang D.H. et al. A unifying pathway for essential hypertension. Am. J. Hypertens. 2005; 18: 431-440.
  44. Sanchez-Lozada L.G., Tapia E., Avila-Casado C. et al. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol. 2002; 283: 1105-1110.
  45. Saito I., Saruta T., Kondon K. еt al. Serum uric acid and the renin- angiotensin system in hypertension. J. Am. Geriatr. Soc. 1978; 26: 241-247.
  46. Waring W.S., Webb D.J., Maxwell S.R.J. et al. Effect of local hyperucemia on endothelial function in the human forearm vascular bed. Br. J Clin. Pharmacol. 2000; 49: 511.
  47. Johnson R.J., Kivlighn S.D., Kim Y.-G. et al. Reappraisal of the pathogenesis and consequences of hyperuricaemia in hypertension, cardiovascular disease, and renal disease. Am. J Kidney Dis. 1999; 33: 225.
  48. Dahlof B., Devereux R.B., Kjeldsen S.E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.
  49. Hoieggen A., Alderman M.H., Kjeldsen S.E. et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004; 65: 1041-1049.
  50. Santos C.X., Anjos E.I., Augusto O. Uric acid oxidation by peroxynitrite: multiple reactions, free radical formation, and amplification of lipid oxidation. Arch. Biochem. Biophys. 1999; 372: 285-294.
  51. Sautin Y.Y., Nakagawa T., Zharikov S., Johnson R.J. Adverse effects of the classical antioxidant uric acid in adipocytes: NADPH oxidase- mediated oxidative/nitrosative stress. Am. J Physiol. Cell. Physiol. 2007; 293: 584-596.
  52. Doehner V., Schoene N., Rauchhaus M. et al. Effects of xantine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation. 2002; 105: 2619-2624.
  53. Coghlan J.G., Flitter W.D., Clutton S.M. et al. Allopurinol pretreatment improves postoperative recovery and reduces lipid peroxidation in patients undergoing coronary artery bypass grafting. J Thorac. Cardiovasc. Surg. 1994; 107: 248-256.
  54. Weimert N.A., Tanke W.F., Sims J.J. Allopurinol as a cardioprotective during coronary artery bypass graft surgery. Ann. Pharmacother. 2003; 37: 1708-1711.
  55. Cappola T.P., Kass D.A., Nelson G.S. et al. Allopurinol improves myocardial effeciency in patients with idiopathic dilated cardiomyopathy. Circulation. 2001; 104: 2407-2411.
  56. George J., Carr E., Davies J., Belch J.J. et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006; 114: 2508-2516.
  57. Waring W.S., McKnight J.A., Webb D.J. et al. Lowering serum urate does not improve endothelial function in patients with type 2 diabetes. Diabetologia. 2007; 50: 2572-2579.
  58. Kang D.H., Park S.K., Lee I.K. et al. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am. Soc. Nephrol. 2005; 16: 3553-3562.
  59. Feldman H.A., Johannes C.B., Derby C.A. et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Prev. Med. 2000; 30: 328-338.
  60. Mirone V., Imbimbo C., Bortolotti A. et al. Cigarette smoking as risk factor for erectile dysfunction: results from an Italian epidemiologicalstudy. Eur. Urol. 2002; 37: 43-49.
  61. Sasayama S., Ishii N., Ishikura F. et al. Men's Health Study: epidemiology of erectile dysfunction and cardiovascular disease. Circ J. 2003; 67: 656-59.
  62. Demir Т. Prevalence of erectile dysfunction in patients with metabolic syndrome. Int. J. Urol. 2006; 13(4): 385-388.
  63. Esposito K., Giugliano F., Martedi E. et al. High proportions of erectile dysfunction in men with the metabolic syndrome. Diabet. Care. 2005; 28: 1201-1203.
  64. Gunduz M.I. et al. Relationship between metabolic syndrome and erectile dysfunction. Asian J. Androl. 2004; 6: 355-358.
  65. Parazzini F., Menchini F.F., Bortolotti A. et al. Frequency and determinants of erectile dysfunction in Italy. Eur. Urol. 2000; 37: 43-49.
  66. Мазо E.Б., Гамидов С.И., Мамедов М.Н., Иремашвили В.В. Патогенез и диагностика эректильной дисфункции у больных метаболическим синдромом. Материалы III Всероссийской науч.-практ. конф. «Актуальные вопросы диагностики и лечения метаболического синдрома». 2006. 71 c.
  67. McCulloch D.K., Young R.L., Prescott R.J. et al. The natural history of impotence in diabetic men. Diabetologia. 1984: 26: 437-440.
  68. NIH Consensus Conference Impotence. NIH Consensus Development Panelon Impotence. JAMA. 1993; 270: 83-90.
  69. Bivalacqua T.J., Usta M.F., Champion H.C. et al. Endothelial dysfunction in erectility’s function: role of the endothelium in erectile physiology and disease. J. Androl. 2003; 24: S17-S37.
  70. Solomon H., Man J.W., Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart. 2003; 89(3): 251-254.
  71. Гиляревский С.Р. Гиперурикемия и хроническая сердечная недостаточность: существует ли причинно-следственная связь? Клиническая нефрология. 2010; 5: 18-22.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies